Drugs / Super1 TCR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06942143 | May 2025 → Apr 2027 expected | lung cancer, melanoma, sarcoma | Guangzhou FineImmune Biotechnology Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Super1 TCR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06942143 ↗ |
| Modality | Cell therapy | “Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors” NCT06942143 ↗ |